In addition, a negative correlation was found between CLDN18.2 expression and HER2 positivity in GC, suggestingthe applicability of CLDN18.2 targeted therapy in HER2-negative GC patients, in accordance with previous studies.13 Notably, 143 (41.6%) of the 344 CLDN18.2-positive GC patients did not express any other biomarker. This evidence concerns the gene ERBB2 and gastric cancer.